Stocks | | The hotel industry may not be as flashy as some other areas for investors. Hotels are rarely the biggest stock gainers, best growth stocks, or the most active stocks on Wall Street, but that doesn’t mean that it’s not worth investing in them. There’s a lot of momentum in the hotel industry—and that means there is potential for stock returns. When investing in the hotel industry, be aware that the hotel industry is cyclical, since its growth has a high correlation with that of the overall stock market. This means that market volatility caused by analyst reports and the latest news is likely to cause volatility in the hotel industry as well. For example, during the financial crisis of 2008, the hotel industry took a major hit. But as part of a diversified portfolio, hotel stocks can be a great investment. Read the Full Story |
|
|
Stocks | |
One of the most interesting components of trading is that each and every day there are new factors that directly influence the prices of securities in the market. That means that every morning at the opening bell, there are plenty of new opportunities that traders can take advantage of. Part of be... Read the Full Story |
|
Markets | |
As a trader, it can be tough to find opportunities in the market if there isn’t a lot of trading volume that day. Even if you think you found a trading setup with a lot of potential, it won’t go anywhere without trading volume. A stock without volume is akin to a car without gasoline. ... Read the Full Story |
|
From Our Partners | | New Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Trump’s Great Gain” has officially begun.
Altucher believes select cryptos could turn $900 into $108,000 over the next 12 months — and he’s laying out the full gameplan in a new presentation. | See Altucher’s Trump crypto prediction here |
|
Markets | | Shares of DocuSign (NASDAQ: DOCU) finished last week at all-time highs after smashing analyst estimates for their earnings and revenue in their Q3 report which was released after Thursday’s session. This comes after upward guidance from management at their last quarterly release in September a... Read the Full Story |
|
Markets | |
If someone were to say that we live in a “post-unicorn era,” they probably wouldn't be too far off. Some have been projecting such an era as far back as 2016, and with the recent issues surrounding WeWork, it's easy to see that if the unicorn era weren't dead before, it probably is now... Read the Full Story |
|
From Our Partners | | A couple of years ago, we started playing with the massive amounts of data that MarketBeat takes in everyday trying to figure out if there was a way to identify short term trading wins. By analyzing earnings data, news sentiment, analyst recommendations, insider transactions and dozens of other data points, we think we’ve found an algorithm that finds interesting short-term stock ideas. We call that algorithm the IdeaEngine and its stock ideas are published on MarketBeat All Access every Monday morning. We make one IdeaEngine idea available free every Monday as an SMS alert. We’ll be releasing the next IdeaEngine alert on Monday morning, so make sure you are signed up before then.  | Get MarketBeat IdeaEngine Alerts (Free) |
|
The Early Bird Stock Of The Day Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer. The company also develops ONC-001, REQORSA as a monotherapy, which is in phase 1 clinical trial to treat advance non-small cell lung cancer; and ONC-002, REQORSA with Tarceva, which is in phase 2 clinical trial to treat non-small cell lung cancer. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas. | View Today's Stock Pick |
|